Dupixent (dupilumab) continues to expand its scope, this time potentially leading it and its developers into a new, multibillion dollar blockbuster market. Dupixent hit the primary and all key secondary endpoints in a phase III study of treating chronic obstructive pulmonary disease (COPD).
One company has developed a promising device and care model to reduce the exacerbations of chronic obstructive pulmonary disease (COPD) that often send patients to the hospital and contribute to accelerated disease progression. Patients who used a wearable remote cardiorespiratory monitoring device developed by Spire Inc. experienced a 64% decrease in cardiopulmonary-specific admissions in a study published in the International Journal of COPD.
Lung Therapeutics Inc. has divulged conjugates comprising epithelial sodium channel (ENaC) blockers (particularly, amiloride and benzamil) covalently linked to peptides to retain in lung tissues reported to be useful for the treatment of cystic fibrosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, primary ciliary dyskinesia, pulmonary emphysema, pneumonia and bronchiectasis.
After posting positive top-line data in August from its phase III ENHANCE-2 study of ensifentrine for treating chronic obstructive pulmonary disease (COPD), Verona Pharma plc now has positive results from the companion phase III study. The ENHANCE-1 trial of ensifentrine as a COPD maintenance treatment hit its primary and key secondary endpoints, prompting the company to say it plans to submit an NDA for the treatment to the U.S. FDA sometime in the first half of 2023.
Ocean University of China has identified novel benzotropone derivatives acting as phosphodiesterase 4 (PDE4) and/or cAMP and cAMP-inhibited cGMP 3ʹ,5ʹ-cyclic phosphodiesterase 10A (PDE10A) inhibitors reported to be useful for the treatment of allergy, inflammatory, neurological and cardiovascular diseases.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Researchers from Jagiellonian University presented the discovery of novel multifunctional inhibitors of phosphodiesterases (PDEs) and transient receptor potential ankyrin 1 (TRPA1) antagonists as potential therapeutic candidates for the treatment for chronic airway disorders.
Researchers from GSK plc presented the discovery and preclinical characterization of novel potent and selective inhaled phosphatidylinositol 4-kinase β (PI4Kβ) inhibitor being developed for the treatment of human rhinovirus (HRV)-induced chronic obstructive pulmonary disease (COPD) exacerbations.
Patients with chronic obstructive pulmonary disease (COPD) may soon have a new way to better manage their health without increasing doctor visits. Nuvoair AB reported that a trial in two U.S. locations showed that 80% of participants with COPD experienced a reduction in hospitalizations as well as improvement in quality of life using the company's integrated digital app and counseling program.
Top-line data from Verona Pharma plc’s phase III ENHANCE-2 study show its inhaled ensifentrine hit the primary and secondary endpoints in treating chronic obstructive pulmonary disease (COPD). Next up: data from the companion phase III, ENHANCE-1, which is expected by the end of 2022.
